A H Mohsen1. 1. Royal Hallamshire Hospital, Sheffield, UK. mike.mckendrick@csuh.nhs.uk
Abstract
BACKGROUND: The epidemiology and natural history of hepatitis C virus (HCV) infection in the UK are uncertain. Previous reports are from small or selected populations such as blood donors or tertiary referral centres. AIMS: To study the epidemiology and natural history of HCV infection. METHODS: Prospective study incorporating five centres within the Trent region. Patients were managed and followed up according to a commonly agreed protocol. SUBJECTS: A total of 1128 HCV positive patients. Patients with haemophilia, human immunodeficiency virus, and chronic renal failure were excluded. RESULTS: Between September 1991 and December 1998, 2546 anti-HCV positive patients were identified of whom 1128 (44%) were enrolled in the cohort. A risk factor(s) for infection was identified in 93.4% of patients who completed the questionnaire; 81% of patients were HCV RNA positive. A total of 397 initial liver biopsies were scored by a single pathologist. These showed a correlation between high alcohol intake and fibrosis score. Multivariate analysis showed fibrosis to be associated with age over 40, past evidence of hepatitis B virus infection, and higher necroinflammatory grade but not with sex, viral genotype, maximum known alcohol intake, estimated duration of infection, or mode of transmission. Twelve (7.8%) of 153 patients who received interferon therapy had sustained serum virus clearance. Sixty six patients have died during the follow up period, 31 with a liver related cause of death. This represents a considerable excess over the expected death rate for a cohort of this age and sex distribution. CONCLUSIONS: HCV infection is an emerging health problem in the Trent region. Identifying risk factors for infection and disease severity will enhance understanding and facilitate improved intervention. An excess mortality in infected individuals is already evident in this unselected cohort.
BACKGROUND: The epidemiology and natural history of hepatitis C virus (HCV) infection in the UK are uncertain. Previous reports are from small or selected populations such as blood donors or tertiary referral centres. AIMS: To study the epidemiology and natural history of HCV infection. METHODS: Prospective study incorporating five centres within the Trent region. Patients were managed and followed up according to a commonly agreed protocol. SUBJECTS: A total of 1128 HCV positive patients. Patients with haemophilia, human immunodeficiency virus, and chronic renal failure were excluded. RESULTS: Between September 1991 and December 1998, 2546 anti-HCV positive patients were identified of whom 1128 (44%) were enrolled in the cohort. A risk factor(s) for infection was identified in 93.4% of patients who completed the questionnaire; 81% of patients were HCV RNA positive. A total of 397 initial liver biopsies were scored by a single pathologist. These showed a correlation between high alcohol intake and fibrosis score. Multivariate analysis showed fibrosis to be associated with age over 40, past evidence of hepatitis B virus infection, and higher necroinflammatory grade but not with sex, viral genotype, maximum known alcohol intake, estimated duration of infection, or mode of transmission. Twelve (7.8%) of 153 patients who received interferon therapy had sustained serum virus clearance. Sixty six patients have died during the follow up period, 31 with a liver related cause of death. This represents a considerable excess over the expected death rate for a cohort of this age and sex distribution. CONCLUSIONS:HCV infection is an emerging health problem in the Trent region. Identifying risk factors for infection and disease severity will enhance understanding and facilitate improved intervention. An excess mortality in infected individuals is already evident in this unselected cohort.
Authors: T Poynard; P Marcellin; S S Lee; C Niederau; G S Minuk; G Ideo; V Bain; J Heathcote; S Zeuzem; C Trepo; J Albrecht Journal: Lancet Date: 1998-10-31 Impact factor: 79.321
Authors: M J Alter; H S Margolis; K Krawczynski; F N Judson; A Mares; W J Alexander; P Y Hu; J K Miller; M A Gerber; R E Sampliner Journal: N Engl J Med Date: 1992-12-31 Impact factor: 91.245
Authors: L B Seeff; Z Buskell-Bales; E C Wright; S J Durako; H J Alter; F L Iber; F B Hollinger; G Gitnick; R G Knodell; R P Perrillo Journal: N Engl J Med Date: 1992-12-31 Impact factor: 91.245
Authors: J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht Journal: N Engl J Med Date: 1998-11-19 Impact factor: 91.245
Authors: I Bakr; C Rekacewicz; M El Hosseiny; S Ismail; M El Daly; S El-Kafrawy; G Esmat; M A Hamid; M K Mohamed; A Fontanet Journal: Gut Date: 2006-01-24 Impact factor: 23.059
Authors: K S Brown; M J Keogh; N Tagiuri; M J Grainge; J S Presanis; S D Ryder; W L Irving; J K Ball; R B Sim; T P Hickling Journal: Clin Exp Immunol Date: 2007-01 Impact factor: 4.330
Authors: Rosilene G Badiani; Vitória Becker; Renata M Perez; Carla A L Matos; Lara B Lemos; Valéria P Lanzoni; Luis Eduardo C Andrade; Alessandra Dellavance; Antonio Eduardo B Silva; Maria Lucia G Ferraz Journal: World J Gastroenterol Date: 2010-08-07 Impact factor: 5.742
Authors: Keyur Patel; Katja S Remlinger; Terence G Walker; Peter Leitner; Joseph E Lucas; Stephen D Gardner; John G McHutchison; Will Irving; Indra Neil Guha Journal: Clin Gastroenterol Hepatol Date: 2014-05-09 Impact factor: 11.382